Spaces:
Running
Running
File size: 68,492 Bytes
9754890 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 1,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n",
" from tqdm.autonotebook import tqdm, trange\n"
]
}
],
"source": [
"from sentence_transformers import SentenceTransformer, util\n",
"import pandas as pd\n",
"import re"
]
},
{
"cell_type": "code",
"execution_count": 2,
"metadata": {},
"outputs": [],
"source": [
"# Target列を分割する関数\n",
"def split_target(target):\n",
" # 指定された区切り文字で分割\n",
" split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
" # 空白文字を除外してリストとして返す\n",
" return [word.strip() for word in split_words if word.strip()]"
]
},
{
"cell_type": "code",
"execution_count": 3,
"metadata": {},
"outputs": [],
"source": [
"basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241202Cancer.csv', index_col=0)\n",
"basedf = basedf.dropna(subset=['試験等のフェーズ'])\n",
"# Target列を分割してTargetWord列を追加\n",
"basedf['TargetWord'] = basedf['Target'].apply(split_target)"
]
},
{
"cell_type": "code",
"execution_count": 4,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
" warnings.warn(\n"
]
}
],
"source": [
"# モデルのロード\n",
"model = SentenceTransformer('all-MiniLM-L6-v2')"
]
},
{
"cell_type": "code",
"execution_count": 9,
"metadata": {},
"outputs": [],
"source": [
"# クエリ\n",
"#query = \"乳がん\"\n",
"query = \"神経膠腫\"\n",
"threshold = 0.7\n",
"# クエリをベクトル化\n",
"query_vec = model.encode(query, convert_to_tensor=True)\n"
]
},
{
"cell_type": "code",
"execution_count": 10,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>Target</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>72</th>\n",
" <td>jRCT2051240141</td>\n",
" <td>NCT05580562</td>\n",
" <td>NaN</td>\n",
" <td>新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO...</td>\n",
" <td>H3 K27M 変異を有する初発びまん性神経膠腫</td>\n",
" <td>H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Able to understand the study procedures and...</td>\n",
" <td>1. Primary spinal tumor.\\r\\n2. Diffuse intrins...</td>\n",
" <td>No limit</td>\n",
" <td>No limit</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Participants will be randomized at baseline in...</td>\n",
" <td>[H3 K27M 変異を有する初発, ん性神経膠腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>103</th>\n",
" <td>jRCT2051240121</td>\n",
" <td>NCT06413706</td>\n",
" <td>NaN</td>\n",
" <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Subjects required to meet all the folloiwng cr...</td>\n",
" <td>Patients who meets any of the following criter...</td>\n",
" <td>No limit</td>\n",
" <td>21age old not</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...</td>\n",
" <td>[悪性神経膠腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>224</th>\n",
" <td>jRCT2031240090</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histologically diagnosed as high grade glio...</td>\n",
" <td>1) Have a history or merger of other malignanc...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>glioblastoma, grade3/4 astrocytoma, grade3 oli...</td>\n",
" <td>Group A: BPC Therapy\\r\\nDepending on the patie...</td>\n",
" <td>[悪性神経膠腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>286</th>\n",
" <td>jRCT2071230124</td>\n",
" <td>NCT06541665</td>\n",
" <td>NaN</td>\n",
" <td>ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40...</td>\n",
" <td>中枢神経系原発リンパ腫</td>\n",
" <td>未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Patients diagnosed with PCNSL\\r\\n2. Patient...</td>\n",
" <td>1.Patients with intraocular PCNSL without brai...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Concomitant administration of ONO-4059 and rit...</td>\n",
" <td>[中枢神経系原発リンパ腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>321</th>\n",
" <td>jRCT2071230114</td>\n",
" <td>NCT06240741</td>\n",
" <td>NaN</td>\n",
" <td>日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを...</td>\n",
" <td>神経内分泌腫瘍（NEN）</td>\n",
" <td>神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>diagnostic purpose</td>\n",
" <td>1. Signed informed consent must be obtained pr...</td>\n",
" <td>1. Inability to complete the needed investigat...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>[68Ga]Ga-DOTA-TATE will be administered intrav...</td>\n",
" <td>[神経内分泌腫瘍（NEN）]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>370</th>\n",
" <td>jRCT2031230511</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>DAREON™-7：神経内分泌癌（NEC）患者の1次治療として，BI 764532点滴静注を...</td>\n",
" <td>肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\...</td>\n",
" <td>パートA：用量漸増の主要目的は，BI 764532の最大耐量（MTD）及び／又は目標用量の拡...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Male or female participants >=18 years old a...</td>\n",
" <td>- Previous treatment in this trial\\r\\n- Curren...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Confidential information</td>\n",
" <td>[肺外神経内分泌癌（, だしメルケル細胞癌，甲状腺髄様癌, グレード3の神経内分泌腫瘍を除く...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>387</th>\n",
" <td>jRCT2031230456</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>JCOG2107E: 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）を対象とし...</td>\n",
" <td>消化器（消化管・肝胆膵）神経内分泌癌</td>\n",
" <td>切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）において、エトポシド＋カルボプラ...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histologically confirmed neuroendocrine car...</td>\n",
" <td>1) Synchronous or metachronous malignancies\\r\\...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm A: Six courses of etoposide + carboplatin ...</td>\n",
" <td>[消化器（消化管, 肝胆膵）神経内分泌癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>459</th>\n",
" <td>jRCT2031230277</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>メトトレキサート基盤寛解導入療法後奏効例の非照射初発中枢神経系原発悪性リンパ腫に対するチラブ...</td>\n",
" <td>中枢神経系原発悪性リンパ腫</td>\n",
" <td>寛解導入療法として大量メトトレキサート（HD-MTX）基盤化学療法実施後に完全奏効（CRまた...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histopathological diagnosis of B cell lymph...</td>\n",
" <td>1) Synchronous or metachronous malignancies.\\r...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Tirabrutinib (480 mg) or placebo taken orally ...</td>\n",
" <td>[中枢神経系原発悪性リンパ腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>473</th>\n",
" <td>jRCT2051230069</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>神経膠腫</td>\n",
" <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td><Cohort 1>\\r\\n All of the following items shal...</td>\n",
" <td><Common to Cohort 1 and Cohort 2>\\r\\n1) Active...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td><cohort1>\\r\\nLomustine 130 mg/m2 orally every ...</td>\n",
" <td>[神経膠腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>529</th>\n",
" <td>jRCT2032230060</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多...</td>\n",
" <td>IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）</td>\n",
" <td>初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>At the time of enrollment, patients will be in...</td>\n",
" <td>Any of the following conditions shall not appl...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>Glioma</td>\n",
" <td>The patient using the product should shave all...</td>\n",
" <td>[IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>549</th>\n",
" <td>jRCT2031230007</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...</td>\n",
" <td>低悪性度神経膠腫、膵癌</td>\n",
" <td>BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion criteria for both cohort A and B\\r\\n...</td>\n",
" <td>1) Active double primary cancer (but not (1)-(...</td>\n",
" <td>12age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>BRAF fusion gene, BRAF rearrangement, low-grad...</td>\n",
" <td>Binimetinib is administered 45 mg orally, twic...</td>\n",
" <td>[低悪性度神経膠腫, 膵癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>563</th>\n",
" <td>jRCT2031220716</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍の患者を対象としたBI 764532と...</td>\n",
" <td>DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍</td>\n",
" <td>用量-毒性関係を評価し，ezabenlimab併用下でのBI 764532の最大耐量（MTD...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>a)Signed and dated, written informed consent f...</td>\n",
" <td>a)Previous treatment with T cell engagers or c...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Confidential information</td>\n",
" <td>[DLL3を発現する小細胞肺癌, その他の神経内分泌腫瘍]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>633</th>\n",
" <td>jRCT2031220511</td>\n",
" <td>NCT05619744</td>\n",
" <td>NaN</td>\n",
" <td>進行小細胞肺癌及びその他の神経内分泌癌患者を対象としてRO7616789の安全性，忍容性，薬...</td>\n",
" <td>小細胞肺癌及びその他の神経内分泌癌</td>\n",
" <td>非盲検多施設共同第Ⅰ相臨床試験</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Life expectancy at least 12 weeks\\r\\n-Eastern...</td>\n",
" <td>-History or clinical evidence of primary centr...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>RO7616789: RO7616789 is administered as a intr...</td>\n",
" <td>[小細胞肺癌, その他の神経内分泌癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>875</th>\n",
" <td>jRCT2031210299</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
" <td>再発悪性神経膠腫</td>\n",
" <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1.\\tEstimated life expectancy >= 3 months\\r\\n2...</td>\n",
" <td>1.\\tPrior therapy with bevacizumab or other an...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Patients will receive DSP-0390 orally once dai...</td>\n",
" <td>[再発悪性神経膠腫]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>14 rows × 39 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"72 jRCT2051240141 NCT05580562 NaN \n",
"103 jRCT2051240121 NCT06413706 NaN \n",
"224 jRCT2031240090 NaN NaN \n",
"286 jRCT2071230124 NCT06541665 NaN \n",
"321 jRCT2071230114 NCT06240741 NaN \n",
"370 jRCT2031230511 NaN NaN \n",
"387 jRCT2031230456 NaN NaN \n",
"459 jRCT2031230277 NaN NaN \n",
"473 jRCT2051230069 NaN NaN \n",
"529 jRCT2032230060 NaN NaN \n",
"549 jRCT2031230007 NaN NaN \n",
"563 jRCT2031220716 NaN NaN \n",
"633 jRCT2031220511 NCT05619744 NaN \n",
"875 jRCT2031210299 NaN NaN \n",
"\n",
" Title \\\n",
"72 新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO... \n",
"103 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n",
"224 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n",
"286 ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40... \n",
"321 日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを... \n",
"370 DAREON™-7：神経内分泌癌（NEC）患者の1次治療として，BI 764532点滴静注を... \n",
"387 JCOG2107E: 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）を対象とし... \n",
"459 メトトレキサート基盤寛解導入療法後奏効例の非照射初発中枢神経系原発悪性リンパ腫に対するチラブ... \n",
"473 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n",
"529 初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多... \n",
"549 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n",
"563 DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍の患者を対象としたBI 764532と... \n",
"633 進行小細胞肺癌及びその他の神経内分泌癌患者を対象としてRO7616789の安全性，忍容性，薬... \n",
"875 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n",
"\n",
" Target \\\n",
"72 H3 K27M 変異を有する初発びまん性神経膠腫 \n",
"103 悪性神経膠腫 \n",
"224 悪性神経膠腫 \n",
"286 中枢神経系原発リンパ腫 \n",
"321 神経内分泌腫瘍（NEN） \n",
"370 肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\... \n",
"387 消化器（消化管・肝胆膵）神経内分泌癌 \n",
"459 中枢神経系原発悪性リンパ腫 \n",
"473 神経膠腫 \n",
"529 IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫） \n",
"549 低悪性度神経膠腫、膵癌 \n",
"563 DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍 \n",
"633 小細胞肺癌及びその他の神経内分泌癌 \n",
"875 再発悪性神経膠腫 \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n",
"72 H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20... 3 NaN \n",
"103 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN \n",
"224 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... 3 NaN \n",
"286 未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及... 1 NaN \n",
"321 神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT... 3 NaN \n",
"370 パートA：用量漸増の主要目的は，BI 764532の最大耐量（MTD）及び／又は目標用量の拡... 1 NaN \n",
"387 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）において、エトポシド＋カルボプラ... 3 NaN \n",
"459 寛解導入療法として大量メトトレキサート（HD-MTX）基盤化学療法実施後に完全奏効（CRまた... 2 NaN \n",
"473 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 1 NaN \n",
"529 初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交... 2 NaN \n",
"549 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A... 2 NaN \n",
"563 用量-毒性関係を評価し，ezabenlimab併用下でのBI 764532の最大耐量（MTD... 1 NaN \n",
"633 非盲検多施設共同第Ⅰ相臨床試験 1 NaN \n",
"875 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN \n",
"\n",
" 無作為化 盲検化 ... purpose \\\n",
"72 無作為化比較 二重盲検 ... treatment purpose \n",
"103 無作為化比較 非盲検 ... treatment purpose \n",
"224 無作為化比較 非盲検 ... treatment purpose \n",
"286 単一群 非盲検 ... treatment purpose \n",
"321 単一群 非盲検 ... diagnostic purpose \n",
"370 非無作為化比較 非盲検 ... treatment purpose \n",
"387 無作為化比較 非盲検 ... treatment purpose \n",
"459 無作為化比較 二重盲検 ... treatment purpose \n",
"473 単一群 非盲検 ... treatment purpose \n",
"529 単一群 非盲検 ... treatment purpose \n",
"549 単一群 非盲検 ... treatment purpose \n",
"563 非無作為化比較 非盲検 ... treatment purpose \n",
"633 単一群 非盲検 ... treatment purpose \n",
"875 単一群 非盲検 ... treatment purpose \n",
"\n",
" Inclusion Criteria \\\n",
"72 1. Able to understand the study procedures and... \n",
"103 Subjects required to meet all the folloiwng cr... \n",
"224 1) Histologically diagnosed as high grade glio... \n",
"286 1. Patients diagnosed with PCNSL\\r\\n2. Patient... \n",
"321 1. Signed informed consent must be obtained pr... \n",
"370 - Male or female participants >=18 years old a... \n",
"387 1) Histologically confirmed neuroendocrine car... \n",
"459 1) Histopathological diagnosis of B cell lymph... \n",
"473 <Cohort 1>\\r\\n All of the following items shal... \n",
"529 At the time of enrollment, patients will be in... \n",
"549 Inclusion criteria for both cohort A and B\\r\\n... \n",
"563 a)Signed and dated, written informed consent f... \n",
"633 -Life expectancy at least 12 weeks\\r\\n-Eastern... \n",
"875 1.\\tEstimated life expectancy >= 3 months\\r\\n2... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"72 1. Primary spinal tumor.\\r\\n2. Diffuse intrins... No limit \n",
"103 Patients who meets any of the following criter... No limit \n",
"224 1) Have a history or merger of other malignanc... 18age old over \n",
"286 1.Patients with intraocular PCNSL without brai... 18age old over \n",
"321 1. Inability to complete the needed investigat... 18age old over \n",
"370 - Previous treatment in this trial\\r\\n- Curren... 18age old over \n",
"387 1) Synchronous or metachronous malignancies\\r\\... 18age old over \n",
"459 1) Synchronous or metachronous malignancies.\\r... 18age old over \n",
"473 <Common to Cohort 1 and Cohort 2>\\r\\n1) Active... 18age old over \n",
"529 Any of the following conditions shall not appl... 18age old over \n",
"549 1) Active double primary cancer (but not (1)-(... 12age old over \n",
"563 a)Previous treatment with T cell engagers or c... 18age old over \n",
"633 -History or clinical evidence of primary centr... 18age old over \n",
"875 1.\\tPrior therapy with bevacizumab or other an... 18age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria \\\n",
"72 No limit NaN NaN \n",
"103 21age old not NaN NaN \n",
"224 75age old under Both NaN \n",
"286 No limit Both NaN \n",
"321 No limit Both NaN \n",
"370 No limit Both NaN \n",
"387 75age old under NaN NaN \n",
"459 No limit NaN NaN \n",
"473 No limit Both NaN \n",
"529 No limit Both NaN \n",
"549 No limit Both NaN \n",
"563 No limit Both NaN \n",
"633 No limit Both NaN \n",
"875 No limit Both NaN \n",
"\n",
" Keyword \\\n",
"72 NaN \n",
"103 NaN \n",
"224 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n",
"286 NaN \n",
"321 NaN \n",
"370 NaN \n",
"387 NaN \n",
"459 NaN \n",
"473 NaN \n",
"529 Glioma \n",
"549 BRAF fusion gene, BRAF rearrangement, low-grad... \n",
"563 NaN \n",
"633 NaN \n",
"875 NaN \n",
"\n",
" Intervention(s) \\\n",
"72 Participants will be randomized at baseline in... \n",
"103 Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt... \n",
"224 Group A: BPC Therapy\\r\\nDepending on the patie... \n",
"286 Concomitant administration of ONO-4059 and rit... \n",
"321 [68Ga]Ga-DOTA-TATE will be administered intrav... \n",
"370 Confidential information \n",
"387 Arm A: Six courses of etoposide + carboplatin ... \n",
"459 Tirabrutinib (480 mg) or placebo taken orally ... \n",
"473 <cohort1>\\r\\nLomustine 130 mg/m2 orally every ... \n",
"529 The patient using the product should shave all... \n",
"549 Binimetinib is administered 45 mg orally, twic... \n",
"563 Confidential information \n",
"633 RO7616789: RO7616789 is administered as a intr... \n",
"875 Patients will receive DSP-0390 orally once dai... \n",
"\n",
" TargetWord \n",
"72 [H3 K27M 変異を有する初発, ん性神経膠腫] \n",
"103 [悪性神経膠腫] \n",
"224 [悪性神経膠腫] \n",
"286 [中枢神経系原発リンパ腫] \n",
"321 [神経内分泌腫瘍（NEN）] \n",
"370 [肺外神経内分泌癌（, だしメルケル細胞癌，甲状腺髄様癌, グレード3の神経内分泌腫瘍を除く... \n",
"387 [消化器（消化管, 肝胆膵）神経内分泌癌] \n",
"459 [中枢神経系原発悪性リンパ腫] \n",
"473 [神経膠腫] \n",
"529 [IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）] \n",
"549 [低悪性度神経膠腫, 膵癌] \n",
"563 [DLL3を発現する小細胞肺癌, その他の神経内分泌腫瘍] \n",
"633 [小細胞肺癌, その他の神経内分泌癌] \n",
"875 [再発悪性神経膠腫] \n",
"\n",
"[14 rows x 39 columns]"
]
},
"execution_count": 10,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"# ターゲットリスト全体を処理\n",
"matched_indices = []\n",
"target_vecs_list = []\n",
"cosine_scores_list = []\n",
"for idx, target_words in enumerate(basedf['TargetWord']):\n",
" # ターゲット内の各単語をベクトル化\n",
" target_vecs = model.encode(target_words, convert_to_tensor=True)\n",
" # コサイン類似度を計算\n",
" cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n",
" target_vecs_list.append(target_vecs)\n",
" cosine_scores_list.append(cosine_scores)\n",
" # 閾値を超えるか確認\n",
" if (cosine_scores >= threshold).any(): # いずれかが閾値を超えている場合\n",
" matched_indices.append(idx)\n",
"\n",
"# 抽出\n",
"matched_df = basedf.iloc[matched_indices]\n",
"matched_df"
]
},
{
"cell_type": "code",
"execution_count": 11,
"metadata": {},
"outputs": [],
"source": [
"# 全データのターゲット列をベクトル化\n",
"target_list = basedf['Target'].tolist()\n",
"target_vecs = model.encode(target_list, convert_to_tensor=True)\n",
"# コサイン類似度を計算\n",
"cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()"
]
},
{
"cell_type": "code",
"execution_count": 13,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>Target</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>103</th>\n",
" <td>jRCT2051240121</td>\n",
" <td>NCT06413706</td>\n",
" <td>NaN</td>\n",
" <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Subjects required to meet all the folloiwng cr...</td>\n",
" <td>Patients who meets any of the following criter...</td>\n",
" <td>No limit</td>\n",
" <td>21age old not</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...</td>\n",
" <td>[悪性神経膠腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>224</th>\n",
" <td>jRCT2031240090</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histologically diagnosed as high grade glio...</td>\n",
" <td>1) Have a history or merger of other malignanc...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>glioblastoma, grade3/4 astrocytoma, grade3 oli...</td>\n",
" <td>Group A: BPC Therapy\\r\\nDepending on the patie...</td>\n",
" <td>[悪性神経膠腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>286</th>\n",
" <td>jRCT2071230124</td>\n",
" <td>NCT06541665</td>\n",
" <td>NaN</td>\n",
" <td>ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40...</td>\n",
" <td>中枢神経系原発リンパ腫</td>\n",
" <td>未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Patients diagnosed with PCNSL\\r\\n2. Patient...</td>\n",
" <td>1.Patients with intraocular PCNSL without brai...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Concomitant administration of ONO-4059 and rit...</td>\n",
" <td>[中枢神経系原発リンパ腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>321</th>\n",
" <td>jRCT2071230114</td>\n",
" <td>NCT06240741</td>\n",
" <td>NaN</td>\n",
" <td>日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを...</td>\n",
" <td>神経内分泌腫瘍（NEN）</td>\n",
" <td>神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>diagnostic purpose</td>\n",
" <td>1. Signed informed consent must be obtained pr...</td>\n",
" <td>1. Inability to complete the needed investigat...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>[68Ga]Ga-DOTA-TATE will be administered intrav...</td>\n",
" <td>[神経内分泌腫瘍（NEN）]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>370</th>\n",
" <td>jRCT2031230511</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>DAREON™-7：神経内分泌癌（NEC）患者の1次治療として，BI 764532点滴静注を...</td>\n",
" <td>肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\...</td>\n",
" <td>パートA：用量漸増の主要目的は，BI 764532の最大耐量（MTD）及び／又は目標用量の拡...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Male or female participants >=18 years old a...</td>\n",
" <td>- Previous treatment in this trial\\r\\n- Curren...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Confidential information</td>\n",
" <td>[肺外神経内分泌癌（, だしメルケル細胞癌，甲状腺髄様癌, グレード3の神経内分泌腫瘍を除く...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>387</th>\n",
" <td>jRCT2031230456</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>JCOG2107E: 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）を対象とし...</td>\n",
" <td>消化器（消化管・肝胆膵）神経内分泌癌</td>\n",
" <td>切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）において、エトポシド＋カルボプラ...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histologically confirmed neuroendocrine car...</td>\n",
" <td>1) Synchronous or metachronous malignancies\\r\\...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm A: Six courses of etoposide + carboplatin ...</td>\n",
" <td>[消化器（消化管, 肝胆膵）神経内分泌癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>459</th>\n",
" <td>jRCT2031230277</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>メトトレキサート基盤寛解導入療法後奏効例の非照射初発中枢神経系原発悪性リンパ腫に対するチラブ...</td>\n",
" <td>中枢神経系原発悪性リンパ腫</td>\n",
" <td>寛解導入療法として大量メトトレキサート（HD-MTX）基盤化学療法実施後に完全奏効（CRまた...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histopathological diagnosis of B cell lymph...</td>\n",
" <td>1) Synchronous or metachronous malignancies.\\r...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Tirabrutinib (480 mg) or placebo taken orally ...</td>\n",
" <td>[中枢神経系原発悪性リンパ腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>473</th>\n",
" <td>jRCT2051230069</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>神経膠腫</td>\n",
" <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td><Cohort 1>\\r\\n All of the following items shal...</td>\n",
" <td><Common to Cohort 1 and Cohort 2>\\r\\n1) Active...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td><cohort1>\\r\\nLomustine 130 mg/m2 orally every ...</td>\n",
" <td>[神経膠腫]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>529</th>\n",
" <td>jRCT2032230060</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多...</td>\n",
" <td>IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）</td>\n",
" <td>初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>At the time of enrollment, patients will be in...</td>\n",
" <td>Any of the following conditions shall not appl...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>Glioma</td>\n",
" <td>The patient using the product should shave all...</td>\n",
" <td>[IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>549</th>\n",
" <td>jRCT2031230007</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...</td>\n",
" <td>低悪性度神経膠腫、膵癌</td>\n",
" <td>BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion criteria for both cohort A and B\\r\\n...</td>\n",
" <td>1) Active double primary cancer (but not (1)-(...</td>\n",
" <td>12age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>BRAF fusion gene, BRAF rearrangement, low-grad...</td>\n",
" <td>Binimetinib is administered 45 mg orally, twic...</td>\n",
" <td>[低悪性度神経膠腫, 膵癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>633</th>\n",
" <td>jRCT2031220511</td>\n",
" <td>NCT05619744</td>\n",
" <td>NaN</td>\n",
" <td>進行小細胞肺癌及びその他の神経内分泌癌患者を対象としてRO7616789の安全性，忍容性，薬...</td>\n",
" <td>小細胞肺癌及びその他の神経内分泌癌</td>\n",
" <td>非盲検多施設共同第Ⅰ相臨床試験</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Life expectancy at least 12 weeks\\r\\n-Eastern...</td>\n",
" <td>-History or clinical evidence of primary centr...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>RO7616789: RO7616789 is administered as a intr...</td>\n",
" <td>[小細胞肺癌, その他の神経内分泌癌]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>875</th>\n",
" <td>jRCT2031210299</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
" <td>再発悪性神経膠腫</td>\n",
" <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1.\\tEstimated life expectancy >= 3 months\\r\\n2...</td>\n",
" <td>1.\\tPrior therapy with bevacizumab or other an...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Patients will receive DSP-0390 orally once dai...</td>\n",
" <td>[再発悪性神経膠腫]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>12 rows × 39 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"103 jRCT2051240121 NCT06413706 NaN \n",
"224 jRCT2031240090 NaN NaN \n",
"286 jRCT2071230124 NCT06541665 NaN \n",
"321 jRCT2071230114 NCT06240741 NaN \n",
"370 jRCT2031230511 NaN NaN \n",
"387 jRCT2031230456 NaN NaN \n",
"459 jRCT2031230277 NaN NaN \n",
"473 jRCT2051230069 NaN NaN \n",
"529 jRCT2032230060 NaN NaN \n",
"549 jRCT2031230007 NaN NaN \n",
"633 jRCT2031220511 NCT05619744 NaN \n",
"875 jRCT2031210299 NaN NaN \n",
"\n",
" Title \\\n",
"103 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n",
"224 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n",
"286 ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40... \n",
"321 日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを... \n",
"370 DAREON™-7：神経内分泌癌（NEC）患者の1次治療として，BI 764532点滴静注を... \n",
"387 JCOG2107E: 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）を対象とし... \n",
"459 メトトレキサート基盤寛解導入療法後奏効例の非照射初発中枢神経系原発悪性リンパ腫に対するチラブ... \n",
"473 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n",
"529 初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多... \n",
"549 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n",
"633 進行小細胞肺癌及びその他の神経内分泌癌患者を対象としてRO7616789の安全性，忍容性，薬... \n",
"875 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n",
"\n",
" Target \\\n",
"103 悪性神経膠腫 \n",
"224 悪性神経膠腫 \n",
"286 中枢神経系原発リンパ腫 \n",
"321 神経内分泌腫瘍（NEN） \n",
"370 肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\... \n",
"387 消化器（消化管・肝胆膵）神経内分泌癌 \n",
"459 中枢神経系原発悪性リンパ腫 \n",
"473 神経膠腫 \n",
"529 IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫） \n",
"549 低悪性度神経膠腫、膵癌 \n",
"633 小細胞肺癌及びその他の神経内分泌癌 \n",
"875 再発悪性神経膠腫 \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n",
"103 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN \n",
"224 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... 3 NaN \n",
"286 未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及... 1 NaN \n",
"321 神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT... 3 NaN \n",
"370 パートA：用量漸増の主要目的は，BI 764532の最大耐量（MTD）及び／又は目標用量の拡... 1 NaN \n",
"387 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）において、エトポシド＋カルボプラ... 3 NaN \n",
"459 寛解導入療法として大量メトトレキサート（HD-MTX）基盤化学療法実施後に完全奏効（CRまた... 2 NaN \n",
"473 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 1 NaN \n",
"529 初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交... 2 NaN \n",
"549 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A... 2 NaN \n",
"633 非盲検多施設共同第Ⅰ相臨床試験 1 NaN \n",
"875 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN \n",
"\n",
" 無作為化 盲検化 ... purpose \\\n",
"103 無作為化比較 非盲検 ... treatment purpose \n",
"224 無作為化比較 非盲検 ... treatment purpose \n",
"286 単一群 非盲検 ... treatment purpose \n",
"321 単一群 非盲検 ... diagnostic purpose \n",
"370 非無作為化比較 非盲検 ... treatment purpose \n",
"387 無作為化比較 非盲検 ... treatment purpose \n",
"459 無作為化比較 二重盲検 ... treatment purpose \n",
"473 単一群 非盲検 ... treatment purpose \n",
"529 単一群 非盲検 ... treatment purpose \n",
"549 単一群 非盲検 ... treatment purpose \n",
"633 単一群 非盲検 ... treatment purpose \n",
"875 単一群 非盲検 ... treatment purpose \n",
"\n",
" Inclusion Criteria \\\n",
"103 Subjects required to meet all the folloiwng cr... \n",
"224 1) Histologically diagnosed as high grade glio... \n",
"286 1. Patients diagnosed with PCNSL\\r\\n2. Patient... \n",
"321 1. Signed informed consent must be obtained pr... \n",
"370 - Male or female participants >=18 years old a... \n",
"387 1) Histologically confirmed neuroendocrine car... \n",
"459 1) Histopathological diagnosis of B cell lymph... \n",
"473 <Cohort 1>\\r\\n All of the following items shal... \n",
"529 At the time of enrollment, patients will be in... \n",
"549 Inclusion criteria for both cohort A and B\\r\\n... \n",
"633 -Life expectancy at least 12 weeks\\r\\n-Eastern... \n",
"875 1.\\tEstimated life expectancy >= 3 months\\r\\n2... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"103 Patients who meets any of the following criter... No limit \n",
"224 1) Have a history or merger of other malignanc... 18age old over \n",
"286 1.Patients with intraocular PCNSL without brai... 18age old over \n",
"321 1. Inability to complete the needed investigat... 18age old over \n",
"370 - Previous treatment in this trial\\r\\n- Curren... 18age old over \n",
"387 1) Synchronous or metachronous malignancies\\r\\... 18age old over \n",
"459 1) Synchronous or metachronous malignancies.\\r... 18age old over \n",
"473 <Common to Cohort 1 and Cohort 2>\\r\\n1) Active... 18age old over \n",
"529 Any of the following conditions shall not appl... 18age old over \n",
"549 1) Active double primary cancer (but not (1)-(... 12age old over \n",
"633 -History or clinical evidence of primary centr... 18age old over \n",
"875 1.\\tPrior therapy with bevacizumab or other an... 18age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria \\\n",
"103 21age old not NaN NaN \n",
"224 75age old under Both NaN \n",
"286 No limit Both NaN \n",
"321 No limit Both NaN \n",
"370 No limit Both NaN \n",
"387 75age old under NaN NaN \n",
"459 No limit NaN NaN \n",
"473 No limit Both NaN \n",
"529 No limit Both NaN \n",
"549 No limit Both NaN \n",
"633 No limit Both NaN \n",
"875 No limit Both NaN \n",
"\n",
" Keyword \\\n",
"103 NaN \n",
"224 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n",
"286 NaN \n",
"321 NaN \n",
"370 NaN \n",
"387 NaN \n",
"459 NaN \n",
"473 NaN \n",
"529 Glioma \n",
"549 BRAF fusion gene, BRAF rearrangement, low-grad... \n",
"633 NaN \n",
"875 NaN \n",
"\n",
" Intervention(s) \\\n",
"103 Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt... \n",
"224 Group A: BPC Therapy\\r\\nDepending on the patie... \n",
"286 Concomitant administration of ONO-4059 and rit... \n",
"321 [68Ga]Ga-DOTA-TATE will be administered intrav... \n",
"370 Confidential information \n",
"387 Arm A: Six courses of etoposide + carboplatin ... \n",
"459 Tirabrutinib (480 mg) or placebo taken orally ... \n",
"473 <cohort1>\\r\\nLomustine 130 mg/m2 orally every ... \n",
"529 The patient using the product should shave all... \n",
"549 Binimetinib is administered 45 mg orally, twic... \n",
"633 RO7616789: RO7616789 is administered as a intr... \n",
"875 Patients will receive DSP-0390 orally once dai... \n",
"\n",
" TargetWord \n",
"103 [悪性神経膠腫] \n",
"224 [悪性神経膠腫] \n",
"286 [中枢神経系原発リンパ腫] \n",
"321 [神経内分泌腫瘍（NEN）] \n",
"370 [肺外神経内分泌癌（, だしメルケル細胞癌，甲状腺髄様癌, グレード3の神経内分泌腫瘍を除く... \n",
"387 [消化器（消化管, 肝胆膵）神経内分泌癌] \n",
"459 [中枢神経系原発悪性リンパ腫] \n",
"473 [神経膠腫] \n",
"529 [IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）] \n",
"549 [低悪性度神経膠腫, 膵癌] \n",
"633 [小細胞肺癌, その他の神経内分泌癌] \n",
"875 [再発悪性神経膠腫] \n",
"\n",
"[12 rows x 39 columns]"
]
},
"execution_count": 13,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n",
"# 入れ子リストをフラットなリストに変換\n",
"flat_indices_d = [idx[0] for idx in matched_indices_d]\n",
"\n",
"# 抽出\n",
"matched_df_d = basedf.iloc[flat_indices_d]\n",
"matched_df_d\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": []
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|